Seeking Alpha


Send Message
View as an RSS Feed
View primarywatcher's Comments BY TICKER:
Latest  |  Highest rated
  • Dewmar International BMC, Inc. (OTC: DEWM) Receives Certification as a Service Disabled Veteran Owned Business [View article]
    While I have enormous respect for our veterans, I have considerable concern with "Dr. Marco Moran" and his ability to cajole investors. As an investor I'd like to see how he plans to make this business wholly accountable for CEO's actions - why is he wearing ALL the hats? Where are the bylaws explaining definition and duties of management and operations whereby Dr. Moran acts as CEO, CFO, and CAO (!); and only one other, Richard Taulli, is acting as President, Treasurer, Secretary, and Director (!!) Who is auditing this company? Where is production facility? I look forward to further illumination on the 4Q13 (?? a press release as to when Dr. Moran intends to file that would be helpful for investors). 3Q13 yielded a whopping -940.95% return on average assets. At any rate, I hold deep respect for his service to our country and applaud the efforts of the LVBOC for their assistance with his efforts to land "additional contracts with some of the largest military bases in the state of Louisiana".
    Feb 25, 2014. 08:01 AM | Likes Like |Link to Comment
  • Our BioPharma Catalyst Watch List [View article]
    Assuming the author here hasn't been sleeping under a rock since MNKD's conference call, where CEO noted his intent to actively pursue partnership with (hopefully) global Rx company, if Phase 3 results are positive (and they were) - the next catalyst on MNKD shareholder calendar is such news. A potential partnership is nothing to sneeze about, and a blatant key reason MNKD stock holds above $5 value today.
    Aug 15, 2013. 05:54 PM | Likes Like |Link to Comment
  • More chatter (previous) on MannKind's (MNKD -1.6%) Afrezza, this time from Brinson Patrick: "We believe AFFINITY is on track to readout mid-August [and] the stock, up 190% YTD, will continue to rise into the readout." Analyst Vernon Bernardino takes the price target on the shares to $9 from $7 and "encourages investors to accumulate positions at these levels." [View news story]
    Difficult to take this seriously...AFFINITY??? - perhaps AFREZZA?
    Jun 23, 2013. 02:55 PM | Likes Like |Link to Comment
  • MannKind (MNKD -12%) takes a hit today on no specific new-related driver. Speculation is circulating that a number of hedge funds are leaning on the shares to flush out supply from retail investors. [View news story]
    If Hedge Funds, et al perpetrated this action - no doubt the SEC should investigate. However, the question remains, WILL investors who were raped by their triggering stop loss markers have the skin to reinvest? The Street, the Fly, Hedge Funds, etc. may have very well cut their nose to spite their face.
    Jun 19, 2013. 09:01 AM | Likes Like |Link to Comment
  • MannKind Management Discusses Q4 2012 Results - Earnings Call Transcript [View article]
    Many thanks for this transcript! Looks like up-coming pivotal months will be:

    March – response from FDA regarding a written request this month to inform the FDA of MNKD's intention to submit a Class 2 resubmission; and,

    August – key trial results for both phase III studies, #171 (type 1 diabetes, AFREZZA using the MedTone inhaler; or AFREZZA using the generation 2 inhaler); and # 174 (type 2 diabetes, assessing the addition of AFREZZA using the generation 2 inhaler)
    Feb 12, 2013. 06:59 AM | 2 Likes Like |Link to Comment